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Abstract
Importance: Natalizumab discontinuation induces the recurrence of Multiple Sclerosis (MS) disease activity: 
Currently no therapeutic approach has been found able to abolish disease reactivation.
Objective: To collect data from patients with MS switching from natalizumab to cyclophosphamide.
Design: Retrospective multicentre study.
Setting: Nine Multiple Sclerosis Centers in Italy.
Participants: A total of 47 patients with clinically definite RR-MS switched to cyclophosphamide after natalizumab 
discontinuation. Two patients were excluded from the analysis because received less than 12 natalizumab infusions. The 
remaining 45 patients were subdivided into two main groups: Early Treatment (period of washout between natalizumab 
and cyclophosphamide 1 to 3 months), Late Treatment (washout between natalizumab and cyclophosphamide higher 
than 3 months).
Intervention: Cyclophosphamide intravenous pulses after natalizumab discontinuation.
Main outcome measure: Number of relapses, Expanded Disability Status Scale scores, number of new T2/fluid-
attenuated inversion recovery lesions and contrast-enhancing lesions on brain magnetic resonance imaging, rebound 
effect, adverse events.
Results: In the Early Treatment group, only 3/23 patients (13%) experienced a clinical relapse and only 2 out 
of 13 (15%) patients showed brain Magnetic Resonance Imaging (MRI) activity at 3 months, while none developed 
MRI activity at 6 months after cyclophosphamide introduction. In the Late Treatment Group 12/22 patients (63%) had 
relapses during the washout period and 4/22 (40%) after the introduction of cyclophosphamide; MRI disease activity 
was shown in 5/9 (56%) at 3 months and in 5/14 (36%) at 6 months after cyclophosphamide introduction.
Conclusions and relevance: These data show that cyclophosphamide could be able to reduce disease 
reactivation after natalizumab, in particular with a short washout period after natalizumab discontinuation. It can be 
suggested that a short period (3-6 months) of cyclophosphamide monthly pulses could be used as “re-induction” 
treatment in patients discontinuing natalizumab.
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Introduction
Natalizumab is a very efficient monoclonal antibody used in 
Relapsing Remitting Multiple Sclerosis (RRMS) [1]. However, despite 
its high efficacy, natalizumab is associated with Progressive Multifocal 
Leukoencephalopathy (PML), a potentially fatal infection caused by the 
John Cunningham virus (JCV) [2].
According to the current risk stratification scheme, JCV antibody 
positivity, natalizumab treatment >2 years, and immunosuppressive 
treatment before natalizumab increase PML risk. Particularly JCV 
antibody-positive patients with at least one additional risk factor 
are at a high PML risk [3-5]. As a consequence these patients and/
or neurologists often choose to discontinue natalizumab therapy. 
Following natalizumab discontinuation, in the majority of patients, 
relapses and Magnetic Resonance Imaging (MRI) activity return to pre-
treatment levels, which peaks 4–7 months after the last infusion. [2,6] 
The risk of return of disease activity appears to be greater in patients 
with high disease activity pre-natalizumab than in those with low 
disease activity [2].
In addition, although a unique definition does not exist, rebound 
phenomena have been described in some patients during natalizumab 
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interruption. There are no established guidelines for the timing and 
choice of treatment in patients who discontinue natalizumab. Disease 
control has been incomplete when patients switched to interferon beta 
(IFNβ) or Glatiramer Acetate (GA), or were treated with high-dose 
corticosteroids [7,8]. There are controversial opinions in the literature 
on the use of Fingolimod (FTY) after natalizumab discontinuation. 
[7,9-15] The aim of our study is to evaluate the efficacy and safety 
of cyclophosphamide (CTX) to reduce disease reactivation after 
natalizumab discontinuation.
Method
Data were collected from nine different Italian MS Centres and 
retrospectively evaluated from clinical records. 47 patients with 
clinically definite RR-MS, who switched to CTX after natalizumab 
discontinuation in the period between May 2011 and September 2014, 
were enrolled.
Two patients were excluded from the analysis because received 
less than 12 natalizumab infusions. The remaining 45 patients were 
subdivided into two main groups according to the period of washout 
between natalizumab and CTX: 23/45 patients had a period of washout 
between 1 to 3 months (Early Treatment) while 22/45 had CTX after at 
least 3 months of washout (Late Treatment) [Figure 1].
Clinical MS stability was defined as the absence of documented 
relapses and the absence of Expanded Disability Status Scale (EDSS) 
progression during the period of examination. MRI activity was defined 
as the appearance of new T2+/FLAIR lesions and/or Gd-enhancing 
lesions. Rebound effect has been evaluated as the recurrence of clinical 
and/or MRI disease activity at a higher level than before natalizumab 
introduction. High dose intravenous methylprednisolone has been 
used in case of clinical relapse according to the normal daily clinical 
activity of each Centre.
Descriptive statistics were used to summarize baseline characteristics 
of patients in each of the two groups: Continuous data were expressed 
as median with interquartile range as measure of variability. Mann-
Whitney and Chi square test were performed to assess differences at 
baseline between groups.
The frequency of relapses and MRI activity (presence/absence 
of lesions) over the follow-up period were reported along with 95% 
confidence intervals computed using Bayesian methods with Jeffrey 
prior [16]. Bootstrap resampling was used to compute 95% confidence 
intervals of EDSS.
Since our study is a retrospective analysis, the CTX-based 
therapeutic protocol was different among Italian MS Centres. The 
protocol applied was constituted by monthly intravenous pulses for 3 or 
6 months after natalizumab discontinuation, but with a different dose 
of CTX infused: the more used protocol in our samples was monthly 
pulses of 800-1000 mg/m2 adjusted for lymphocytes count at the nadir.
In our analysis we report the cumulative dose of CTX expressed as 
milligrams for body surface (mg/m2).
In Italy the CTX is an approved drug for autoimmune diseases of 
the Nervous System (Note 4 AIFA) and informed consent was obtained 
from the patients before starting therapy. No specific ethics committee 
approval was needed according to local regulations.
Results
Demographic and baseline characteristics. The demographic 
and clinical features of the patients are summarized in [Table 1]. No 
statistical differences were observed between the two groups.
The main reason for natalizumab discontinuation was the risk of 
PML (respectively 78% and 73%): no data on anti-JCV antibodies Index 
were available at the time of the study. Developments of neutralising 
antibodies, adverse events or lack of efficacy were minor reasons and 
they were equal distributed between the 2 groups.
Relapse and EDSS after CTX
In the Early Treatment group, only 3/23 patients (13%) experienced 
a clinical relapse: one patient after 2 monthly pulses of CTX and two 
patients after 3 monthly pulses of CTX. Interestingly, one patient 
experienced 2 relapses after CTX introduction and he was the only with 
a washout period of 3 months. The other two patients that experienced 
1 relapse each after CTX, had respectively 1 and 2 months of washout 
from natalizumab. In addition, in the washout period between 
natalizumab and CTX, two patients present a clinical relapse, one of 
which had experienced a clinical relapse also after CTX treatment, 
indicating a very aggressive disease. Median EDSS improved at the end 
of follow-up (median EDSS 3,82 at the end of follow-up, median EDSS 
4,0 at natalizumab withdrawal). No patients had rebound. Mean follow-
up was 9,3 months (range 1-16).
In the Late Treatment Group 12/22 patients (54%) had relapses 
Figure 1: Enrolment of Patients in the Study: 47 patients switched to 
CTX after natalizumab discontinuation: two patients were excluded from the 
analysis because received less than 12 natalizumab infusions. The remaining 
45 patients were subdivided into two main groups:  Early Treatment (period 
of washout between natalizumab and CTX 1 to 3 months), Late Treatment 
(washout between natalizumab and CTX > 3 months).
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during the washout period (mean 10, range 4-42 months) and 4/22 
(18%) after the introduction of CTX. In 9 patients (41%) a rebound 
effect was described. A median increase of 1-point EDSS has been seen 
in this group of patients (median EDSS 4,07 at the end of follow-up, 
median EDSS 3,0 at natalizumab withdrawal).
MRI disease activity
A total of 61 brain MRI scans had been performed in 45 patients 
after CTX introduction (31/61 in Early Treatment and 30/61 in Late 
Treatment). In the Early Treatment group only 2 out of 13 (15%) 
patients showed brain MRI activity at 3 months while none developed 
MRI activity at 6 months. On the contrary in the Late Treatment group 
MRI disease activity was shown in 5/9 (56%) at 3 months and in 5/14 
(36%) at 6 months after CTX introduction [Table 2].
Adverse events 
The CTX was well tolerated and no patient discontinued treatment 
for adverse events. We report adverse events in five patients: pneumonia, 
urinary infection, alopecia, amenorrhoea and asymptomatic 
neutropenia.
                  Early Treatment Late Treatment p-value
                  (N=23) (N=22)  
Age at the time of discontinuation of natalizumab 40.3 (34.3-49.7) 36 (31.9-42.1) 0.09
EDSS score at natalizumab initiation 4.0 (2.6-4.5) 3.0 (2.0-4.5) 0.28
EDSS score at natalizumab withdrawal 4.0 (2.8-5.5) 3.0 (1.1-4.5) 0.24
Natalizumab infusions 28 (24-36) 26 (22-34) 0.55
Relapses in the year before natalizumab 2 (1-2) 2 (1.25-3) 0.13
MRI active scans in the year before natalizumab 100% (21) 91% (20) 0.14
Primary reason for stopping natalizumab (%) 0.9
	 Risk of PML 78% (18) 73% (16)
	 Adverse events 4% (1) 5% (1)
	 Efficacy issue 9% (2) 9% (2)
	 Development of neutralizing antibodies against         
natalizumab 9% (2) 9% (2)
	 Pregnancy 0% (0) 5% (1)
Cumulative dose of CTX (mg/m2) 3000 (2700-5625) 5100 (3000-6375) 0.3
Follow up post CTX (months) 11 (6.5-12) 7 (4-16.8)  0.91
Abbreviations: EDSS=Expanded Disability Status Scale, MRI=Magnetic Resonance Imaging, PML=Progressive Multifocal Leukoencephalopathy, CTX=Cyclophosphamide.
Table 1: Shows demographic and baseline characteristics of patients. 
Early Treatment Late Treatment OR P-value
% (N/T) 95% CI % (N/T) 95% CI
Relapses during wash-out 13% (3/23) 3.95; 32.09 54% (12/22) 40.87; 81.76 10.86 0.002
Relapses during CTX 13% (3/23) 3.81; 30.87 18% (4/22) 15.31; 69.63 4.44 0.095
EDSS at the end of CTX 3.82 3.11; 4.61 4.07 3.37; 5.02 1.23 0.688
MRI Pre Natalizumab
Active 100% (23/23) 89.76; 100 91%(20/22) 73.91; 98.06 0.174 0.200
Inactive 0% (0/23) 0; 10.24 9% (2/22) 1.94; 26.09
MRI Pre CTX
Active 30% (7/23) 14.77; 50.68 58% (11/19) 35.9; 77.68 3.14 0.078
Inactive 70% (16/23) 49.32; 85.23 42% (8/19) 22.32; 64.1
MRI 3-months
Active 15% (2/13) 3.34; 40.9 56% (5/9) 25.41; 82.7 6.87 0.059
Inactive 85% (11/13) 59.1; 96.66 44% (4/9) 17.30; 74.59
MRI 6-months
Active 0% (0/15) 0; 15.82 36% (5/14) 15.15; 61.55 17.94 0.012
Inactive 100% (15/15) 84.81; 100 64% (9/14) 38.45; 84.85
MRI 12-months
Active 0% (0/3) 0; 53.56 57% (4/7) 23.45; 86.11 9.00 0.128
Inactive 100% (3/3) 46.44; 100 43% (3/7) 13.88; 76.55
Abbreviations: MRI=Magnetic Resonance Imaging, CTX=Cyclophosphamide, N=Number of Patients, T=Number of Censored Patients. 
Table 2: MRI disease activity: Shows brain MRI scans before natalizumab, before CTX and after CTX introduction. Before natalizumab introduction MRI was active in 
the majority of patients in both groups. Before CTX introduction MRI was active in the most part of the Late Treatment group. After CTX introduction in the Early Treatment 
group only 2 out of 13 patients showed brain MRI activity at 3 months while none developed MRI activity at 6 months. In the Late Treatment group MRI disease activity was 
shown in 5/9 at 3 months and in 5/14 at 6 months after CTX introduction. 
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Discussion
As far as we know, this is the first study on CTX after discontinuation 
of natalizumab. Our results showed an important efficacy of CTX after 
natalizumab discontinuation: only 3 patients (13%) experienced a 
clinical relapse when CTX treatment is started early (1-3 months).
CTX could be able to reduce disease reactivation after natalizumab 
discontinuation for marked immunosuppression and an anti-
inflammatory immune effect.
CTX is an alkylating agent used to halt rapidly progressive 
forms of multiple sclerosis, high doses of CTX produce marked 
immunosuppression and an anti-inflammatory immune deviation. 
CTX effectively reduces the number of circulating T and B cells in 
addition to creating a more favourable cytokine balance, shifting away 
from autoimmune Th1 responses and reductions in interleukin 12 (IL-
12) and interferon gamma (IFN-γ). This is the rationale for its use in the 
treatment of autoimmune diseases, including Multiple Sclerosis. CTX 
and its metabolites are also capable of penetrating the blood–brain 
barrier and can exert direct intrathecal immunologic effects. These 
beneficial biologic effects are potentially favourable for disease control 
after natalizumab discontinuation [17].
As we have enrolled patients in the period between May 2011 and 
September 2014 not many therapeutic options were available at that 
time: In particular neither BG12 nor alemtuzumab nor ocrelizumab 
were available. Off-label use of rituximab should also be an option but 
it is also at risk of PML development limitating its use in these kinds of 
patients.
In the literature there are controversial opinions on the treatment 
strategies for patients who discontinue natalizumab therapy. There are 
a large number of studies analysing the use of FTY: some have reported 
increased relapse rates and severe relapses in patients switching to FTY 
after natalizumab discontinuation [12,13,17,18]. Other studies reported 
that FTY have a potential role to reduce disease reactivation between 
15% and 30% [7,9-11,19,20] Nevertheless, due to the fact that FTY 
steady state kinetics is achieved only two months after initiation, it could 
be a longer time to achieve a complete control of disease reactivation 
[21]. On the contrary CTX has intrathecal immunologic rapid effects 
that could play a crucial role to arrest MS disease reactivation, which 
peaks 4–7 months after the last infusion of natalizumab. 
For these reasons cyclophosphamide was preferred in our 
population characterised by a very aggressive disease course. Our 
study confirms, moreover, that washout between natalizumab and 
other Disease Modifying Treatment (DMTs) should be shorter than 3 
months, as other have described [7,9,14].
In the Late Treatment group we observed a higher number of relapses 
after CTX introduction; moreover the only patient with 3 months of 
washout in the Early Treatment group experienced 2 clinical relapses 
after the introduction of CTX. In addition, the risk of relapse during 
the washout is correlated with MS disease activity before natalizumab 
initiation and with the duration of the washout. The risk increased 
significantly for patients with a washout of 3 months or longer. The use 
of methylprednisolone or an immunomodulatory drug did not mitigate 
the risk of relapse. Conversely, patients who had a short washout (<3 
months) had a lower risk of relapse. In fact, in our study in the Late 
Treatment Group 12 (63%) patients had more relapses than in the Early 
Treatment group during the washout period between natalizumab and 
CTX. Our data support choosing a short switch period (2 months or 
less) between natalizumab and other DMT.
CTX has an acceptable safety profile; it is important to monitor the 
patients during and after CTX therapy for toxicity, dose-related adverse 
events, and the risk for long-term effects due to immunosuppression, 
as the risk of opportunistic infections like PML. The main cause of 
natalizumab discontinuation is the risk of PML, no data has been 
reported in the literature that quantify the PML risk after CTX therapy, 
but it must be taken into consideration the possibility of cumulative 
risk. This potential risk has to be considered as much as the high risk of 
disease activity after natalizumab discontinuation.
The retrospective nature of this study is an important limitation 
as the different therapeutic CTX protocol among Italian MS Centres. 
Despite these limitations, this report represents a first study of using 
CTX after natalizumab discontinuation. Of course, we are aware that 
a larger sample size, longer follow-up and unique infusion protocol are 
needed to confirm our preliminary results.
According to our results, we propose to standardize the protocol to 
monthly intravenous pulses, using a dose of 1000 mg/m2 per pulse, with 
a short natalizumab-CTX washout (<3 months). Due to the potential 
cumulative risk of infections, a short course (3-6 months) of CTX 
therapy should be recommended and it can precede the initiation of 
other DMTs, as BG12 or Fingolimod, almost in selected patients with 
an aggressive pre-natalizumab MS.
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